Factors affecting drug release from liposomes

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 1, 2010, Pages 111-123

  Lindner, Lars H ^a,b   Hossann, Martin ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Max Planck Innovation GmbH   (Germany)

Author keywords

Drug delivery; Drug release; Liposome; Phospholipid; Stimuli sensitive liposome; Thermosensitive liposome

Indexed keywords

1,2 DILINOLEOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOGLYCEROL; 1,2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOSERINE; 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHOGLYCEROL; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHOSERINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOGLYCEROL; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOSERINE; 3,5 BIS(DODECYLOXY)BENZOIC ACID; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CAMPTOTHECIN; CIPROFLOXACIN; CYTARABINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; FLOXURIDINE; IRINOTECAN; LIPOSOME; MILTEFOSINE; PERIFOSINE; THERMODOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ACIDITY; ASPERGILLOSIS; BREAST CANCER; CANDIDIASIS; CARDIOTOXICITY; CELL CONTACT; CHEMICAL BOND; CHEMICAL STRUCTURE; CRYPTOCOCCAL MENINGITIS; DIFFUSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; ENCAPSULATION; HEAT SENSITIVITY; HUMAN; HYDROPHOBICITY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; MEMBRANE COMPONENT; MEMBRANE PERMEABILITY; MENINGITIS; METASTASIS; MOLECULAR INTERACTION; MUCORMYCOSIS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PHASE TRANSITION; PINOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; TEMPERATURE DEPENDENCE; THERMODYNAMICS; TUMOR VASCULARIZATION; ULTRASOUND; VISCERAL LEISHMANIASIS;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPID METABOLISM; LIPOSOMES; TISSUE DISTRIBUTION;

EID: 73849121484     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 4(2):145-160.
2. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 13(1): 238-252.
3. New RRC, Black CDV, Parker RJ, Puri A, Scherphof GL: Liposomes in biological systems. In: Liposomes: A practical approach. New RRC (Ed), Oxford University Press, New York, NY, USA (1997):221-252.
4. Ong W, Yang Y, Cruciano AC, McCarley RL: Redox-triggered contents release from liposomes. J Am Chem Soc (2008) 130(44):14739-14744.
5. Banerjee J, Hanson AJ, Gadam B, Elegbede AI, Tobwala S, Ganguly B, Wagh AV, Muhonen WW, Law B, Shabb JB, Srivastava DK et al: Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem (2009) 20(7):1332-1339.
6. Kaasgaard T, Andresen TL, Jensen SS, Holte RO, Jensen LT, Jørgensen K: Liposomes containing alkylated methotrexate analogues for phospholipase A2 mediated tumor targeted drug delivery. Chem Phys Lipids (2009) 157(2):94-103.
7. Jo S, Lee HY, Kim J: Glucose-sensitive liposomes incorporating hydrophobically modified glucose oxidase. Lipids (2008) 43(10):937-943.
8. Boomer JA, Qualls MM, Inerowicz HD, Haynes RH, Patri VS, Kim J, Thompson DH: Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem (2009) 20(1):47-59.
9. Needham D, Anyarambhatla G, Kong G, Dewhirst MW: A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res (2000) 60(5):1197-1201.
10. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M: Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res (2004) 10(6):2168-2178.
11. Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, Pruitt AF, Klein A, Case B, Thrall DE, Needham D et al: Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res (2006) 12(13):4004-4010.
12. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ: Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 13(9):2722-2727.
13. Schroeder A, Kost J, Barenholz Y: Ultrasound, liposomes, and drug delivery: Principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids (2009) 162 (1-2):1-16.
14. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urtti A: Gold nanoparticles enable selective light-induced contents release from liposomes. J Control Release (2007) 122(1):86-93.
15. Wu G, Mikhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA: Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J Am Chem Soc (2008) 130(26):8175-8177.
16. Volodkin DV, Skirtach AG, Möhwald H: Near-IR remote release from assemblies of liposomes and nanoparticles. Angew Chem Int Ed Engl (2009) 48(10):1807-1809.
17. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, Minko T: Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release (2008) 130(2):107-114.
18. Elbayoumi TA, Torchilin VP: Tumor-targeted nanomedicines: Enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 15(6):1973-1980.
19. Guyard-Dangremont V, Desrumaux C, Gambert P, Lallemant C, Lagrost L: Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. Comp Biochem Physiol B Biochem Mol Biol (1998) 120(3):517-525.
20. Lindner LH, Hossann M, Vogeser M, Teichert N, Wachholz K, Eibl H, Hiddemann W, Issels RD: Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: Active ingredient and mediator of drug release. J Control Release (2008) 125(2): 112-120.
21. Hillaireau H, Couvreur P: Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci (2009) 66(17):2873-2896.
22. Momekova D, Rangelov S, Yanev S, Nikolova E, Konstantinov S, Romberg B, Storm G, Lambov N: Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur J Pharm Sci (2007) 32(4-5): 308-317.
23. Auguste DT, Furman K, Wong A, Fuller J, Armes SP, Deming TJ, Langer R: Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release (2008) 130(3):266-274.
24. Iyer AK, Khaled G, Fang J, Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today (2006) 11(17-18):812-818.
25. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, Wiel-Ambagtsheer G, van Tiel ST, Eggermont AMM, Ten Hagen TLM: Tumor necrosis factor α mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res (2007) 67(19):9455-9462.
26. Cheong I, Huang X, Bettegowda C, Diaz LA, Jr, Kinzler KW, Zhou S, Vogelstein B: A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science (2006) 314(5803):1308-1311.
27. Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y: Direct comparison of two PEGylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? J Control Release (2007) 118(2):204-215.
28. Charrois GJ, Allen TM: Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta (2004) 1663 (1-2):167-177.
29. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD: Coencapsulation of irinotecan and floxuridine into low cholesterol- containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2007) 1768(3):678-687.
30. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, Mayer LD: Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res (2007) 16(8):361-374.
31. Batist G, Gelmon KA, Chi KN, Miller WH, Chia SKL, Mayer LD, Swenson CE, Janoff AS, Louie AC: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res (2009) 15(2):692-700.
32. Marrink S, Berendsen HJ: Simulation of water transport through a lipid membrane. J Phys Chem (1994) 98(15):4155-4168.
33. Xiang T, Anderson BD: Liposomal drug transport: A molecular perspective from molecular dynamics simulations in lipid bilayers. Adv Drug Deliv Rev (2006) 58(12-13):1357-1378.
34. van Meer G, Voelker DR, Feigenson GW: Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol (2008) 9(2):112-124.
35. Chono S, Fukuchi R, Seki T, Morimoto K: Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release (2009) 137(2):104-109.
36. Volodkin D, Mohwald H, Voegel J, Ball V: Coating of negatively charged liposomes by polylysine: Drug release study. J Control Release (2007) 117(1):111-120.
37. Shimanouchi T, Ishii H, Yoshimoto N, Umakoshi H, Kuboi R: Calcein permeation across phosphatidylcholine bilayer membrane: Effects of membrane fluidity, liposome size, and immobilization. Colloids Surf B Biointerfaces (2009) 73(1): 156-160.
38. Alipour M, Halwani M, Omri A, Suntres ZE: Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm (2008) 355 (1-2):293-298.
39. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR: Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta (1999) 1416(1-2):1-10.
40. Huang Z, Jaafari MR, Szoka FC: Disterolphospholipids: Nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem Int Ed Engl (2009) 48(23):4146-4149.
41. Koklic T, Zeisig R, Sentjurc M: Interaction of alkylphospholipid liposomes with MT-3 breast-cancer cells depends critically on cholesterol concentration. Biochim Biophys Acta (2008) 1778(12):2682-2689.
42. Papahadjopoulos D, Jacobson K, Nir S, Isac T: Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta (1973) 311(3):330-348.
43. Kim JH, Kim MW: Temperature effect on the transport dynamics of a small molecule through a liposome bilayer. Eur Phys J E Soft Matter (2007) 23(3):313-317.
44. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB: Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm (2008) 349(1-2):38-46.
45. Bornmann C, Graeser R, Esser N, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam U, Schaechtele C, Massing U et al: A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol (2008) 61(3):395-405.
46. Watanabe M, Kawano K, Toma K, Hattori Y, Maitani Y: In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release (2008) 127(3):231-238.
47. Bemporad D, Luttmann C, Essex JW: Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. Biochim Biophys Acta (2005) 1718(1-2):1-21.
48. Cohen BE, Bangham AD: Diffusion of small non-electrolytes across liposome membranes. Nature (1972) 236(5343):173-174.
49. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC: Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol (2009) 64(4):741-751.
50. Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR: Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1758(1):55-64.
51. Johnston MJ, Edwards K, Karlsson G, Cullis PR: Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 18(2):145-157.
52. Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O'Halloran TV: Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc (2006) 128(41):13348-13349.
53. Dicko A, Frazier AA, Liboiron BD, Hinderliter A, Ellena JF, Xie X, Cho C, Weber T, Tardi PG, Cabral-Lilly D, Cafiso DS et al: Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm Res (2008) 25(7):1702-1713.
54. Scherphof G, Roerdink F, Waite M, Parks J: Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta (1978) 542(2):296-307.
55. Shabbits JA, Chiu GN, Mayer LD: Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release (2002) 84(3):161-170.
56. Hossann M, Wiggenhorn M, Schwerdt A, Wachholz K, Teichert N, Eibl H, Issels RD, Lindner LH: In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta (2007) 1768(10):2491-2499.
57. Hosokawa T, Sami M, Kato Y, Hayakawa E: Alteration in the temperature-dependent content release property of thermosensitive liposomes in plasma. Chem Pharm Bull (2003) 51(11):1227-1232.
58. Sakaguchi N, Kojima C, Harada A, Kono K: Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: Their ability to sensitize stable liposomes to pH. Bioconjug Chem (2008) 19(5):1040-1048.
59. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R: Design of liposomes for enhanced local release of drugs by hyperthermia. Science (1978) 202(4374):1290-1293.
60. Mills JK, Needham D: Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta (2005) 1716(2):77-96.
61. Sandström MC, Johansson E, Edwards K: Structure of mixed micelles formed in PEG-lipid/lipid dispersions. Langmuir (2007) 23(8):4192-4198.
62. Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F: Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia (2008) 24(6):475-482.
63. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW: Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 99(1):53-63.
64. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM et al: Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 56(5):1011-1018.
65. Langereis S, Keupp J, van Velthoven JLJ, de Roos IHC, Burdinski D, Pikkemaat JA, Grüll H: A temperature-sensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery. J Am Chem Soc (2009) 131(4):1380-1381.
66. Wang T, Hossann M, Reinl HM, Peller M, Eibl H, Reiser M, Issels RD, Lindner LH: In vitro characterization of phosphatidylglyceroglycerol-based thermosensitive liposomes with encapsulated 1H MR T1-shortening gadodiamide. Contrast Media Mol Imaging (2008) 3(1):19-26.
67. Peller M, Schwerdt A, Hossann M, Reinl HM, Wang T, Sourbron S, Ogris M, Lindner LH: MR characterization of mild hyperthermiainduced gadodiamide release from thermosensitive liposomes in solid tumors. Invest Radiol (2008) 43(12):877-892.
68. Hayashi H, Kono K, Takagishi: Temperature sensitization of liposomes using copolymers of N-isopropylacrylamide. Bioconjug Chem (1999) 10(3):412-418.
69. Han HD, Shin BC, Choi HS: Doxorubicin-encapsulated thermosensitive liposomes modified with poly(Nisopropylacrylamide-co-acrylamide): Drug release behavior and stability in the presence of serum. Eur J Pharm Biopharm (2006) 62(1):110-116.
70. Paasonen L, Romberg B, Storm G, Yliperttula M, Urtti A, Hennink WE: Temperature-sensitive poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjug Chem (2007) 18(6):2131-2136.
71. Weissleder R: A clearer vision for in vivo imaging. Nat Biotechnol (2001) 19(4):316-317.